The deal size was increased to $700M in common stock from $650M in common stock. Morgan Stanley, Goldman Sachs, JPMorgan and Jefferies acted as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target raised to $108 from $98 at Stifel
- Cytokinetics price target raised to $119 from $101 at RBC Capital
- Cytokinetics price target raised to $103 from $90 at Morgan Stanley
- Maxwell Skor Lifts Cytokinetics Price Target to $103 and Reiterates Buy on Strong Phase 3 ACACIA-HCM Results for Aficamten
- Cytokinetics Earnings Call Highlights Launch, Trial Wins